Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria: * Patient must have documentation of histologically confirmed and measurable Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL; * Patient must have symptomatic and progressive disease; * Patient must have received prior alkylating agent(s) and be fludarabine refractory; * Patient must have the adequate organ functions; * Patient's Eastern Cooperative Oncology Group performance (ECOG) status must be 0-2; Exclusion Criteria: * Patient with de novo PLL; * Patient with secondary malignancy that will limit survival ≤5 years; * Patient with prior allogenic or autologous bone marrow transplant or peripheral blood stem cell transplant ≤12 months; * Patient receiving an investigational agent or an approved agent for an investigational purpose within last 4 weeks prior to study entry; * Patient with known history of glucose-6-phosphate dehydrogenase deficiency; * Patient with autoimmune hemolytic anemia; * Patient with known Central Nervous System involvement; * Patient with active, uncontrolled serious bacterial, viral or fungal infections The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.